{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:19:58Z","timestamp":1793744398536,"version":"4.6.1"},"reference-count":47,"publisher":"Cambridge University Press (CUP)","issue":"5","license":[{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","award":["MRC- RFA-IFSP-01-2013"],"award-info":[{"award-number":["MRC- RFA-IFSP-01-2013"]}],"id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Psychol. Med."],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec id=\"S0033291721003809_sec_a1\"><jats:title>Background<\/jats:title><jats:p>Progressive brain structural MRI changes are described in schizophrenia and have been ascribed to both illness progression and antipsychotic treatment. We investigated treatment effects, in terms of total cumulative antipsychotic dose, efficacy and tolerability, on brain structural changes over the first 24 months of treatment in schizophrenia.<\/jats:p><\/jats:sec><jats:sec id=\"S0033291721003809_sec_a2\" sec-type=\"methods\"><jats:title>Methods<\/jats:title><jats:p>A prospective, 24-month, single-site cohort study in 99 minimally treated patients with first-episode schizophrenia, schizophreniform and schizoaffective disorder, and 98 matched healthy controls. We treated the patients according to a fixed protocol with flupenthixol decanoate, a long-acting injectable antipsychotic. We assessed psychopathology, cognition, extrapyramidal symptoms and BMI, and acquired MRI scans at months 0, 12 and 24. We selected global cortical thickness, white matter volume and basal ganglia volume as the regions of interest.<\/jats:p><\/jats:sec><jats:sec id=\"S0033291721003809_sec_a3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>The only significant group \u00d7 time interaction was for basal ganglia volumes. However, patients, but not controls, displayed cortical thickness reductions and increases in white matter and basal ganglia volumes. Cortical thickness reductions were unrelated to treatment. White matter volume increases were associated with lower cumulative antipsychotic dose, greater improvements in psychopathology and cognition, and more extrapyramidal symptoms. Basal ganglia volume increases were associated with greater improvements in psychopathology, greater increases in BMI and more extrapyramidal symptoms.<\/jats:p><\/jats:sec><jats:sec id=\"S0033291721003809_sec_a4\" sec-type=\"conclusions\"><jats:title>Conclusions<\/jats:title><jats:p>We provide evidence for plasticity in white matter and basal ganglia associated with antipsychotic treatment in schizophrenia, most likely linked to the dopamine blocking actions of these agents. Cortical changes may be more closely related to the neurodevelopmental, non-dopaminergic aspects of the illness.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s0033291721003809","type":"journal-article","created":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T08:04:48Z","timestamp":1632384288000},"page":"2050-2059","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":32,"title":["Antipsychotic treatment effects and structural MRI brain changes in schizophrenia"],"prefix":"10.1017","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1250-6888","authenticated-orcid":false,"given":"Robin","family":"Emsley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"du Plessis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lebogang","family":"Phahladira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilmar K.","family":"Luckhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederika","family":"Scheffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Kilian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Retha","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanelle","family":"Buckle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonginkosi","family":"Chiliza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Asmal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2021,9,23]]},"reference":[{"key":"S0033291721003809_ref35","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291710002163"},{"key":"S0033291721003809_ref36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00716-z"},{"key":"S0033291721003809_ref24","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.4.361"},{"key":"S0033291721003809_ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2015.06.016"},{"key":"S0033291721003809_ref9","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S113099"},{"key":"S0033291721003809_ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(02)00302-X"},{"key":"S0033291721003809_ref13","volume-title":"Structured clinical interview for DSM-IV axis I disorders, patient edition (SCID-P)","author":"First","year":"1994"},{"key":"S0033291721003809_ref47","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/17.2.325"},{"key":"S0033291721003809_ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2012.09.006"},{"key":"S0033291721003809_ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s10354-007-0478-7"},{"key":"S0033291721003809_ref7","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa025"},{"key":"S0033291721003809_ref14","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2009.09060802"},{"key":"S0033291721003809_ref17","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbs118"},{"key":"S0033291721003809_ref25","first-page":"CD001470","article-title":"Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders","volume":"6","author":"Mahapatra","year":"2014","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"S0033291721003809_ref28","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2012.47"},{"key":"S0033291721003809_ref30","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291709005315"},{"key":"S0033291721003809_ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2018.04.023"},{"key":"S0033291721003809_ref42","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2012.116"},{"key":"S0033291721003809_ref20","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2574"},{"key":"S0033291721003809_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2014.05.023"},{"key":"S0033291721003809_ref11","first-page":"438","article-title":"Volumetric changes in the basal ganglia after antipsychotic monotherapy: A systematic review","volume":"20","author":"Ebdrup","year":"2013","journal-title":"Current Medical Chemistry"},{"key":"S0033291721003809_ref45","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.1941"},{"key":"S0033291721003809_ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2011.06.029"},{"key":"S0033291721003809_ref15","doi-asserted-by":"publisher","DOI":"10.1006\/nimg.2001.1037"},{"key":"S0033291721003809_ref18","doi-asserted-by":"publisher","DOI":"10.1017\/S003329171500210X"},{"key":"S0033291721003809_ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.pscychresns.2010.04.016"},{"key":"S0033291721003809_ref19","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2010.199"},{"key":"S0033291721003809_ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2011.01.032"},{"key":"S0033291721003809_ref2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.12050674"},{"key":"S0033291721003809_ref10","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300710"},{"key":"S0033291721003809_ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2005.11.004"},{"key":"S0033291721003809_ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2015.02.008"},{"key":"S0033291721003809_ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2016.06.002"},{"key":"S0033291721003809_ref46","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2013.19"},{"key":"S0033291721003809_ref27","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbx180"},{"key":"S0033291721003809_ref34","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X13666150429002536"},{"key":"S0033291721003809_ref22","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.111.095323"},{"key":"S0033291721003809_ref21","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"S0033291721003809_ref38","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2015.63"},{"key":"S0033291721003809_ref32","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2015.209"},{"key":"S0033291721003809_ref1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.3.441"},{"key":"S0033291721003809_ref31","volume-title":"MATRICS consensus battery manual","author":"Nuechterlein","year":"2006"},{"key":"S0033291721003809_ref44","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2014.00264"},{"key":"S0033291721003809_ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2005.02.013"},{"key":"S0033291721003809_ref23","first-page":"CD008016","article-title":"Maintenance treatment with antipsychotic drugs for schizophrenia","volume":"5","author":"Leucht","year":"2012","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"S0033291721003809_ref3","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.58.5.461"},{"key":"S0033291721003809_ref29","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.116.182683"}],"container-title":["Psychological Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0033291721003809","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T08:57:25Z","timestamp":1685091445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0033291721003809\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,23]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0033291721003809"],"URL":"https:\/\/doi.org\/10.1017\/s0033291721003809","relation":{},"ISSN":["0033-2917","1469-8978"],"issn-type":[{"value":"0033-2917","type":"print"},{"value":"1469-8978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,23]]},"assertion":[{"value":"Copyright \u00a9 The Author(s), 2021. Published by Cambridge University Press","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http:\/\/creativecommons.org\/licenses\/by\/4.0\/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}